(Health-NewsWire.Net, October 24, 2017 ) ReportsWeb.com published “20s Proteasome-Pipeline Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. According to the recently published report '20s Proteasome - Pipeline Review, H2 2017'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides. Key Players Amgen Inc Celgene Corp For more information about this report http://www.reportsweb.com/20s-proteasome-pipeline-review-h2-2017 It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Multiple Myeloma (Kahler Disease) , Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia (CLL) , Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM) , Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL) , Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Tuberculosis and Uterine Leiomyoma (Uterine Fibroids) . Scope
- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome - The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects - The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011169462/sample Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Table of Contents Introduction 5 Publisher Report Coverage 5 20s Proteasome - Overview 6 20s Proteasome - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 12 Products under Development by Universities/Institutes 16 20s Proteasome - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 20s Proteasome - Companies Involved in Therapeutics Development 22 Amgen Inc 22 Celgene Corp 24 20s Proteasome - Drug Profiles 25 carfilzomib - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 marizomib - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Inquire before Buying at http://www.reportsweb.com/buy&RW00011169461/buy/2000 Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com About ReportsWeb: ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|